IGF2BP1 and metabolic dysfunction-associated steatohepatitis: Results of IPA upstream regulator analysis pointed to significant activation of the insulin-like growth factor 1 (IGF1) pathway and IGF2BP1 in NASH-associated HCCs, but not in HCV+ HCCs (Figure 1A and Supplementary Table S3).